Anti-PD1 and anti-PDL1 targeted therapies have significantly improved the clinical outcome of patients (especially those with PD-L1-positive tumour cells, or tumour and immune cells) afflicted by various type of cancers and are currently undergoing clinical trials for patients with OC [45,46]. Here, CD274 is linked to cancer.